Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,621 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Los Angeles, California • Pasadena, California • San Francisco, California + 11 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Interventions: dexamethasone, ranibizumab, sham; Drug · Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions: Faricimab, Port Delivery System with Ranibizumab; Drug · Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Faricimab; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Bakersfield, California • Modesto, California • Orlando, Florida + 13 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: WF-AO-OCT; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions: Not listed
Lead sponsor: Michael Abramoff; Other
Eligibility: 45 Years to 120 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cystoid Macular Edema,, Retinal Thickening
Interventions: 2. Xibrom (Bromfenac), 1. Pred Forte; Drug
Lead sponsor: Center For Excellence In Eye Care; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Diabetic Retinopathy (DR)
Interventions: Diabetic Retinopathy screening Point of Care Artificial Intelligence; Diagnostic Test
Lead sponsor: Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health; Other
Eligibility: 22 Years and older
Enrollment: 548 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Chula Vista, California • San Diego, California

Conditions: Age Related Macular Degeneration
Interventions: Longvida curcumin, placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pigmentary Maculopathy, Pigmentary Retinopathy, Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Retinitis Pigmentosa
Interventions: Anterior Chamber (AC) tap; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: Scott Raymond; Other
Eligibility: 50 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Age-related Macular Degeneration
Interventions: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet; Drug
Lead sponsor: Snyder, Robert W., M.D., Ph.D., P.C.; Individual
Eligibility: 50 Years to 85 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Macular Hole, RPE Detachment, Epiretinal Membrane, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years to 95 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Retinitis Pigmentosa
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Healthy, Muscular Dystrophy, Retinal Degeneration, Skin Diseases, Virus Diseases
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 1978 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fibromyalgia, Musculoskeletal Pain
Interventions: S-Cone Stimulating Chromatic Light, Equal-Energy White Light; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more

Conditions: Hypertension, Retinal Disorder, Cognitive Impairment
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Geographic Atrophy
Interventions: PEGCETACOPLAN (APL-2); Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Bakersfield, California • Beverly Hills, California • Encino, California + 2 more

Conditions: Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions: Remigromig, Aflibercept 2.0 mg; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more

Conditions: Cone-Rod Degeneration, Rod-Cone Degeneration
Interventions: VR Mobility Tool; Diagnostic Test
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 5 Years to 120 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Safety and Efficacy of Faricimab in Patients With NPDR

Adaptive Optics for Ophthalmic Technologies

Retinal Therapy Guided by 3D OCT Image Analysis

Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

Biomarkers In Retinitis Pigmentosa (BIRP)

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

Dose Ranging Study of Carbidopa-levodopa

Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies

Oral N-acetylcysteine for Retinitis Pigmentosa

Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

Light Bulb Stimuli to Reduce Chronic Pain

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

DETECT and Retinal Outcomes in Hypertension

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease